Protalix BioTherapeutics, Inc. (PLX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Protalix BioTherapeutics, Inc. (PLX) is up 10.6% since the beginning of the year. At $2 per share, PLX is trading 37.6% below its 52-week high of $3. Investors who bought $1,000 worth of PLX shares 5 years ago would now be looking at an investment worth $897.

Protalix BioTherapeutics, Inc. (PLX) has returned 10.56% so far this year and 24.37% over the past 12 months. Over the last ten years, PLX has returned -12.88% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since May 15, 1998, PLX's average daily return is +0.45%, while the average monthly return is +9.09%. At this rate, an investment would double in approximately 0.7 years.

Historically, 38% of months were positive and 62% were negative. The best month was Dec 2005 with a return of +2,025.0%, while the worst month was Oct 2007 at -85.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.

On a daily basis, PLX closed higher 33% of trading days. The best single day was Dec 31, 1999 with a return of +1,300.0%, while the worst single day was Oct 25, 2007 at -82.5%.

Protalix BioTherapeutics, Inc. has an annualized alpha of 190.61%, beta of 0.70, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 18, 1998.

• This stock participated in 85.18% of S&P 500 Index downside but only -22.65% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.70 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PLX ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Protalix BioTherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Protalix BioTherapeutics, Inc. was 99.91%, occurring on Jan 27, 2022. The portfolio has not yet recovered.

The current Protalix BioTherapeutics, Inc. drawdown is 99.77%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Protalix BioTherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Protalix BioTherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.